Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

CRB-913

Other · developed by Corbus Pharmaceuticals

Phase 1 Most advanced trial
CRBP Developer
1 Registered trials

What is CRB-913?

CRB-913 is an investigational drug studied in Obese But Otherwise Healthy Participants.

At a glance

Drug type
Other
Therapy area
Metabolic
Developer
Corbus Pharmaceuticals Inc. (CRBP)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07310901 Phase 1 Obese But Otherwise Healthy Participants Active not recruiting CRBP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Obese But Otherwise Healthy Participants

More from Corbus Pharmaceuticals

CRB-601 Phase 1/2 Extension Phase 2 JBT-101 Phase 3 Sutantatug Envedotin Phase 3

Follow CRBP, the company behind CRB-913

See CRBP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CRBP catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.